latest News
WAKEFIELD, MA September 15, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, reports today receiving additional data from a U.S. Regional Biocontainment Laboratory (RBL) collected during ongoing in vitro testing supporting Brilacidin as a potential treatment for SARS-CoV-2, the novel coronavirus responsible for COVID-19. In human lung epithelial cell line experiments performed at the RBL, Brilacidin in combination with Remdesivir, compared to Remdesivir-only treated conditions, showed a statistically significant and synergistic inhibition of SARS-CoV-2. Of particular note, overall viral load was reduced by 99.85 percent in one combination experiment, with remaining virus dropping to near undetectable levels. Brilacidin's is ready to show what it can do in human trials. The reason I believe it will be successful is based on the previous testing: Brilacidin is the only Covid19 which is virucidal. It has the ability to quickly open the viral capsid to destroy the virus. This will result in a rapid reduction of the viral load and should in the trials result in lower mortality and morbidity. Brilacidin blocks Covi19 attachment to the cells which stops the cells from becoming infected. Plus ,evidence has shown it may inhibit the main protease to prevent viral replication. Unlike Regereron's monoclonal antibody drug,Brilacidin has been studied in clinical trials in over 500 patients and has an excellent safety profile and good pharmokinetics. In addition it is a broad spectrum antibiotic and has demonstrated equivalency to Daptomycin. Best of all preclinical study have found immunomodulating abilities which have the potential to reduce the inflammation and edema in the alveoli and small bronchioles which results in pulmonary failure and is the most common cause of death. Now the RBLs report it is synergistic with Remdesivir and lowers the virus by over 99%. Thanks to poster Farrell.